Middle East In Vitro Diagnostics Market Poised for $2.15 Billion Boom by 2032

The Middle East In Vitro Diagnostics (IVD) Market is set to reach $2.15 billion by 2032, growing at a CAGR of 4.1% from 2025 to 2032, according to Meticulous Research®. This growth is powered by rising chronic and infectious diseases, increased healthcare spending, and a strong push for point-of-care (PoC) and rapid diagnostics. Countries like Saudi Arabia and the UAE are making strategic investments in healthcare modernization, including genomics and lab automation under initiatives like Saudi Vision 2030.

A major driver is the alarming rise in diabetes—with over 4.3 million cases in Saudi Arabia alone—which demands constant glucose and complication monitoring, creating continuous demand for lab-based and PoC diagnostics. Infectious diseases such as MERS-CoV further accelerate diagnostic demand.

While innovation is surging—especially in molecular diagnostics, wearable sensors, and home-based testing—challenges persist. These include high costs, lack of skilled technicians, and regulatory fragmentation that slows new product entry. Urban-rural disparities also affect test availability.

Future trends point toward personalized diagnostics, domestic manufacturing, and AI integration to enhance accuracy and workflow. Key players include Abbott, Roche, Siemens Healthineers, Thermo Fisher, and Bio-Rad.

With strong public-private partnerships and a shift toward early screening and digital health, the Middle East IVD market is entering a transformative decade.

👉 Download Sample Report